CD274 and non-small cell lung carcinoma: This could challenge the development of anti-miR-155 therapy, but also presents an opportunity since elevated PD-L1 expression often positively correlates with the prognosis of patients receiving immune checkpoint inhibitors (ICIs) in NSCLC (9,10).